IRONWOOD PHARMACEUTICALS INC(IRWD)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
IRONWOOD PHARMACEUTICALS INC (IRWD) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IRWD at 60.8/100 on a 32-signal composite quality model, placing it at rank #834 of 2,962 stocks — the top half of the AI-ranked universe. IRWD scores in the top quartile across balance sheet strength (99.2), profitability (94.4), free cash flow (94.1). Areas of concern include institutional flow (4.1) and revenue growth (20.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 22.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), IRONWOOD PHARMACEUTICALS INC reports quarterly revenue of $113.0M, net income of $51.3M, an operating margin of 70.2%. Top institutional holders of IRWD by reported 13-F value include BlackRock, ARMISTICE CAPITAL, Sarissa Capital Management, based on the most recent SEC filings. IRWD trades on the Nasdaq exchange and files with the SEC under CIK 1446847. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IRWD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IRONWOOD PHARMACEUTICALS INC directly from SEC EDGAR.
AI Quality Score
60.8/100
AI Rank
#834
Revenue
$113.0M
Net Income
$51.3M
Operating Margin
70.2%
IRWD key financials by period
IRONWOOD PHARMACEUTICALS INC reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$296.2M
$24.0M
33.3%
FY 2024
10-K
$351.4M
$880.0K
26.5%
FY 2023
10-K
$442.7M
$-1.0B
—
FY 2022
10-K
$410.6M
$175.1M
61.0%
FY 2021
10-K
$413.8M
$528.4M
56.1%
FY 2020
10-K
$389.5M
$106.2M
36.7%
Institutions holding IRWD
Institutional investors reporting a position in IRONWOOD PHARMACEUTICALS INC on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-06 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Revenue grew 33% YoY to $113.0M on higher LINZESS net profit share from AbbVie, driving net income up to $51.3M from $23.6M as expenses fell 15%.
Biggest Revenue Drivers
AbbVie (North America)$110.9M+28% YoY
Increase in share of net profits from LINZESS U.S. sales, driven primarily by increased net price and increased prescription demand
AbbVie (Europe and other)$1.1M+23% YoY
Biggest Revenue Drivers
Total revenue: $113.0M+33% YoY
AbbVie (North America)$110.9M+28% YoY
Increase in share of net profits from LINZESS U.S. sales, driven primarily by increased net price and increased prescription demand
AbbVie (Europe and other)$1.1M+23% YoY
Asahi Kasei Therapeutics (Japan, apraglutide)$0.5Mswung from -$2.7M to +$0.5M
Prior-year period included a $2.9M cumulative revenue reduction from increased estimated development costs
Astellas (Japan)$0.4M-7% YoY
Grand Life Sciences (China)$0.08M+7% YoY
Largest Expense Items
Research and development$22.4M-4% YoY
Decrease driven by lower external costs for the discontinued IW-3300 program and linaclotide, partially offset by higher apraglutide costs
Selling, general and administrative$11.3M-33% YoY
Decrease due to lower compensation/employee-related expenses and lower professional services expenses
Margins: Income from operations rose to $79.3M from $45.3M as revenue growth (+33% YoY) outpaced a 15% decline in total costs and expenses, driven by lower R&D and SG&A spend.
Watch Items from the Filing
In July 2026, Ironwood and AbbVie sued Alkem Laboratories over an ANDA challenge to LINZESS patents; the filing triggers an automatic FDA approval stay until December 12, 2028.
Cash and cash equivalents fell to $79.1M from $215.5M after repaying the $200.0M principal on the 2026 Convertible Notes at maturity in June 2026.
In May 2026, AstraZeneca assigned its China (including Hong Kong and Macau) linaclotide collaboration rights to Grand Life Sciences, a small but newly transitioned revenue territory.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
